Lamivudine/raltegravir
Lamivudine/raltegravir, sold under the brand name Dutrebis, is a combination medication of lamivudine and raltegravir which is used in the treatment of HIV/AIDS.[1] It is taken by mouth.[1] Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes.[1] It was approved for medical use in the United States in 2015.[1]
Combination of | |
---|---|
Lamivudine | Reverse-transcriptase inhibitor |
Raltegravir | Integrase inhibitor |
Clinical data | |
Trade names | Dutrebis |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
KEGG |
References
- "Dutrebis (lamivudine and raltegravir)" (PDF). FDA. Retrieved 10 December 2017.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.